Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency
Background: Newborns are referred primary carnitine deficiency (PCD) when a low free carnitine (C0) concentration (<10 μmol/L) is detected, leading to high false-positive referrals. To improve the follow-up protocol for PCD, various acylcarnitines and the summations were comprehensively evaluated...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | International Journal of Neonatal Screening |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2409-515X/11/2/47 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850167939169255424 |
|---|---|
| author | Haijuan Zhi Siyu Chang Ting Chen Lili Liang Wenjuan Qiu Huiwen Zhang Xuefan Gu Lianshu Han |
| author_facet | Haijuan Zhi Siyu Chang Ting Chen Lili Liang Wenjuan Qiu Huiwen Zhang Xuefan Gu Lianshu Han |
| author_sort | Haijuan Zhi |
| collection | DOAJ |
| description | Background: Newborns are referred primary carnitine deficiency (PCD) when a low free carnitine (C0) concentration (<10 μmol/L) is detected, leading to high false-positive referrals. To improve the follow-up protocol for PCD, various acylcarnitines and the summations were comprehensively evaluated in the present study. Methods: A retrospective study was performed using samples due to low C0 concentration. Data were available for 72 patients with genetically confirmed PCD, whereafter C0 with the selected sum of (butyrylcarnitine (C4) + isovalerylcarnitine (C5)) was validated in an additional cohort study including about 80,000 samples. Results: In the discovery study, C4, acetylcarnitine (C2) and C5 exhibited significant discriminant power in distinguishing PCDs from NoPCDs. The area under the ROC curve (AUC) was 99.792% (C4), 98.715% (C2) and 98.620% (C5). The excellent performances in sensitivity, specificity, negative predictive value, positive predictive value (PPV) and accuracy indexes suggested that C4, C2 and C5 would be ideal auxiliary indicators in improving the diagnostic performance of C0 for PCD. Multivariate ROC curve-based exploratory analysis showed that C5, C4 and C2 were the most top-ranked features in differentiating PCDs from NoPCDs. AUC for C4 + C5 was the highest with a cutoff required for 100% sensitivity at 0.181 μmol/L. In the validation cohort, adding C4 + C5 in the NBS program could elevate PPV from 0.75% to 1.54%. Conclusions: Our work revealed that C4 + C5 summation should be used as the auxiliary quantization indicator to reduce false-positive results for PCD. |
| format | Article |
| id | doaj-art-2178fb208cd443928f39d68819314001 |
| institution | OA Journals |
| issn | 2409-515X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Neonatal Screening |
| spelling | doaj-art-2178fb208cd443928f39d688193140012025-08-20T02:21:06ZengMDPI AGInternational Journal of Neonatal Screening2409-515X2025-06-011124710.3390/ijns11020047Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine DeficiencyHaijuan Zhi0Siyu Chang1Ting Chen2Lili Liang3Wenjuan Qiu4Huiwen Zhang5Xuefan Gu6Lianshu Han7Department of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaDepartment of Pediatric Endocrinology and Genetic Metabolism, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiaotong University School of Medicine, Shanghai 200092, ChinaBackground: Newborns are referred primary carnitine deficiency (PCD) when a low free carnitine (C0) concentration (<10 μmol/L) is detected, leading to high false-positive referrals. To improve the follow-up protocol for PCD, various acylcarnitines and the summations were comprehensively evaluated in the present study. Methods: A retrospective study was performed using samples due to low C0 concentration. Data were available for 72 patients with genetically confirmed PCD, whereafter C0 with the selected sum of (butyrylcarnitine (C4) + isovalerylcarnitine (C5)) was validated in an additional cohort study including about 80,000 samples. Results: In the discovery study, C4, acetylcarnitine (C2) and C5 exhibited significant discriminant power in distinguishing PCDs from NoPCDs. The area under the ROC curve (AUC) was 99.792% (C4), 98.715% (C2) and 98.620% (C5). The excellent performances in sensitivity, specificity, negative predictive value, positive predictive value (PPV) and accuracy indexes suggested that C4, C2 and C5 would be ideal auxiliary indicators in improving the diagnostic performance of C0 for PCD. Multivariate ROC curve-based exploratory analysis showed that C5, C4 and C2 were the most top-ranked features in differentiating PCDs from NoPCDs. AUC for C4 + C5 was the highest with a cutoff required for 100% sensitivity at 0.181 μmol/L. In the validation cohort, adding C4 + C5 in the NBS program could elevate PPV from 0.75% to 1.54%. Conclusions: Our work revealed that C4 + C5 summation should be used as the auxiliary quantization indicator to reduce false-positive results for PCD.https://www.mdpi.com/2409-515X/11/2/47primary carnitine deficiencyfree carnitineacylcarnitine summationmachine learningscreening and diagnosisfalse positive |
| spellingShingle | Haijuan Zhi Siyu Chang Ting Chen Lili Liang Wenjuan Qiu Huiwen Zhang Xuefan Gu Lianshu Han Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency International Journal of Neonatal Screening primary carnitine deficiency free carnitine acylcarnitine summation machine learning screening and diagnosis false positive |
| title | Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency |
| title_full | Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency |
| title_fullStr | Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency |
| title_full_unstemmed | Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency |
| title_short | Assessment and Application of Acylcarnitines Summations as Auxiliary Quantization Indicator for Primary Carnitine Deficiency |
| title_sort | assessment and application of acylcarnitines summations as auxiliary quantization indicator for primary carnitine deficiency |
| topic | primary carnitine deficiency free carnitine acylcarnitine summation machine learning screening and diagnosis false positive |
| url | https://www.mdpi.com/2409-515X/11/2/47 |
| work_keys_str_mv | AT haijuanzhi assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT siyuchang assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT tingchen assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT lililiang assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT wenjuanqiu assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT huiwenzhang assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT xuefangu assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency AT lianshuhan assessmentandapplicationofacylcarnitinessummationsasauxiliaryquantizationindicatorforprimarycarnitinedeficiency |